Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.000%10/1
-
Market price (% of par)
-
103.64%
-
Total 13F principal
-
$162,027,500
-
Principal change
-
-$17,068,500
-
Total reported market value
-
$178,795,000
-
Number of holders
-
13
-
Value change
-
-$13,557,562
-
Number of buys
-
6
-
Number of sells
-
6
Institutional Holders of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 as of Q1 2021
As of 31 Mar 2021,
KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 was held by
13 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$162,027,500
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, Farallon Capital Management, L.L.C., LAZARD ASSET MANAGEMENT LLC, Davidson Kempner Capital Management LP, STEELHEAD PARTNERS LLC, CAPSTONE INVESTMENT ADVISORS, LLC, Opti Capital Management, LP, CNH PARTNERS LLC, JPMORGAN CHASE & CO, and CREDIT SUISSE AG/.
This page lists
14
institutional bondholders reporting positions
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.